A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

A method for preventing stroke in a patient suffering from atrial fibrillation wherein the patient has no risk factors for major bleeding events the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate optionally in the form of a pharmaceutically acceptable salt thereof.

The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover...

The present invention relates to a process for preparing solid drug form with warfarin sodium salt in the form of isopropanol clathrate as an active substance in combination with usual pharmaceutical adjuvants exhibiting a great extent of volume uniformity wherein the preparation process of the present invention is characterized in that a starting powder mixture of a drug form is mixed within a low-speed mixer for a period of 5 to 30 minutes at a rate of 15 to 80 rpm , preferably for a period of...

PURPOSE: A manufacturing method of chiral warfarin derivatives is provided to efficiently manufacture optically active substance with high optical purity with the high yield by using 1 mole% of chiral catalyst. CONSTITUTION: A manufacturing method of chiral warfarin derivatives is a method of manufacturing chiral warfarin derivatives by using chiral catalyst